ArticleJournal of breast cancer2026
Long-term Outcomes of Acellular Dermal Matrix Use in Breast-Conserving Surgery: A Single-Institution Study.
Article in Journal of breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeThis study evaluated long-term postoperative outcomes and complications after breast-conserving surgery (BCS) with acellular dermal matrix (ADM) insertion.
methodsWe retrospectively reviewed the data of patients treated between July 2015 and August 2021. Patients who did not undergo postoperative follow-up were excluded. Clinical characteristics, treatment information, and postoperative complications were collected from the electronic medical records. Complications were classified as major (requiring hospitalization or surgical intervention) or minor (manageable in an outpatient setting). ADM removals were categorized as early (≤ 6 months postoperatively) or delayed (> 6 months).
resultsAmong the 236 patients (median follow-up, 71.7 months), complications occurred in 119 (50.4%): 22 major (9.3%) and 97 minor (41.1%). Infection was the most common major complication (13/22, 59.2%), whereas seroma was the predominant minor complication (87/97, 89.7%). In univariate analysis, no clinicopathological or treatment-related factors were associated with major complications. ADM removal was performed in 28 patients (11.9%), including nine with local recurrence and 19 unrelated to recurrence (8.1%). Among the 19 nonrecurrent removals, 13 (68.4%) occurred > 6 months after surgery, most commonly due to infection (12/19, 63.2%).
conclusionComplications after BCS with ADM insertion were common during the long-term follow-up. The 9.3% major complication rate and 8.1% reoperation rate for ADM removal are not negligible. These findings highlight the need for careful patient selection and long-term surveillance of patients undergoing BCS with ADM insertion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.